Persons D L, Robinson R A, Hsu P H, Seelig S A, Borell T J, Hartmann L C, Jenkins R B
Departments of Laboratory Medicine and Pathology and Medical Oncology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA.
Clin Cancer Res. 1996 May;2(5):883-8.
Fluorescence in situ hybridization was performed on touch preparations from 55 primary infiltrating ductal carcinomas of the breast to determine numeric chromosome abnormalities. The frequency of aneusomy, measured by both nondisomy and chromosomal gain, was determined for chromosomes X, 4, 6-12, 17, and 18 with the use of chromosome-specific, alpha-satellite DNA probes. The presence of chromosome-specific numeric abnormalities was correlated with established clinicopathological parameters, including tumor size, lymph node involvement, tumor grade, estrogen receptor level, and menopause status. In addition, a case-control study was performed to explore a possible association between chromosome-specific aneusomy and recurrence in lymph-node-negative patients. Although chromosomes 8 and 6 were most frequently aneusomic, numeric abnormalities of chromosomes 4 and 11 were most strongly associated with established prognostic factors. For chromosomes 4 and 11, strong associations were found with tumor involvement of lymph nodes and increased tumor size, along with a weaker association with tumor grade. In addition, numeric abnormalities of the following chromosomes were associated with the corresponding prognostic factors: chromosomes X, 7, and 12 with lymph node status; chromosomes 10, 17, and 6 with tumor size; and chromosomes 7, 12, 17, and X with tumor grade. No correlations were observed with estrogen receptor level or menopause status. In the case-control study performed on isolated nuclei of paraffin-embedded tissue from lymph node-negative breast cancer patients (19 cases and 19 controls), the gain of chromosome 4 was correlated with disease progression. These findings suggest that chromosome-specific aneusomy is associated with certain established prognostic factors and may be associated with disease progression.
对55例原发性乳腺浸润性导管癌的触片进行荧光原位杂交,以确定染色体数目异常情况。使用染色体特异性α卫星DNA探针,测定X、4、6 - 12、17和18号染色体的非二体性和染色体增加所测量的非整倍体频率。染色体特异性数目异常的存在与既定的临床病理参数相关,包括肿瘤大小、淋巴结受累情况、肿瘤分级、雌激素受体水平和绝经状态。此外,进行了一项病例对照研究,以探讨染色体特异性非整倍体与淋巴结阴性患者复发之间的可能关联。尽管8号和6号染色体最常出现非整倍体,但4号和11号染色体的数目异常与既定的预后因素关联最为密切。对于4号和11号染色体,发现与淋巴结肿瘤受累和肿瘤大小增加有很强的关联,与肿瘤分级的关联较弱。此外,以下染色体的数目异常与相应的预后因素相关:X、7和12号染色体与淋巴结状态;10、17和6号染色体与肿瘤大小;7、12、17和X号染色体与肿瘤分级。未观察到与雌激素受体水平或绝经状态的相关性。在对淋巴结阴性乳腺癌患者石蜡包埋组织的分离细胞核进行的病例对照研究(19例病例和19例对照)中,4号染色体的增加与疾病进展相关。这些发现表明,染色体特异性非整倍体与某些既定的预后因素相关,并且可能与疾病进展相关。